

**The University of Western Ontario**  
**BIOLOGICAL AGENTS REGISTRY FORM**  
**Approved Biohazards Subcommittee: October 14, 2011**  
**Biosafety Website: [www.uwo.ca/humanresources/biosafety/](http://www.uwo.ca/humanresources/biosafety/)**

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario (UWO) or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biological agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biological agents being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1<sup>st</sup> edition 1996, Canadian Food Inspection Agency (CFIA).

Electronically completed forms are to be submitted to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190 or to [jstanle2@uwo.ca](mailto:jstanle2@uwo.ca)) for distribution to the Biohazards Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or [biosafety@uwo.ca](mailto:biosafety@uwo.ca). If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: [www.uwo.ca/humanresources/biosafety/](http://www.uwo.ca/humanresources/biosafety/).

Please ensure that all questions are fully and clearly answered. Failure to do so will lead to the form being returned, which will cause delays in your approval and frustration for you and your colleagues on the Committee.

**If you are re-submitting this form as requested by the Biohazards Subcommittee, please make modifications to the form in bold print, highlighted in yellow. Please re-submit forms electronically.**

PRINCIPAL INVESTIGATOR:	<b>Walter L. Siqueira</b>
DEPARTMENT:	<b>Dentistry</b>
ADDRESS:	<b>DSB 0071</b>
PHONE NUMBER:	<b>519-661-2111 ext. 86104</b>
EMERGENCY PHONE NUMBER(S):	<b>226-777-4848</b>
EMAIL:	<b><a href="mailto:walter.siqueira@schulich.uwo.ca">walter.siqueira@schulich.uwo.ca</a></b>

Location of experimental work to be carried out :

Building :	<b>DSB</b>	Room(s):	<b>0015</b>
Building :	<b>DSB</b>	Room(s):	<b>0031B</b>
Building :		Room(s):	

**\*For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 15.0, Approvals).**

FUNDING AGENCY/AGENCIES: CIHR

GRANT TITLE(S): Composition, Structure and Function of Human Acquired Enamel Pellicle

UNDERGRADUATE COURSE NAME(IF APPLICABLE): \_\_\_\_\_

List all personnel working under Principal Investigators supervision in this location:

Name	UWO E-mail Address	Date of Biosafety Training
Carina Boghossian	<a href="mailto:cboghoss@uwo.ca">cboghoss@uwo.ca</a>	30-Mar-2012
Dusa Vukosavljevic	<a href="mailto:dvukosav@uwo.ca">dvukosav@uwo.ca</a>	5-Mar-2010
Meltem Bakkal	<a href="mailto:mbakkal@uwo.ca">mbakkal@uwo.ca</a>	
William Custodio	<a href="mailto:wcustodi@uwo.ca">wcustodi@uwo.ca</a>	14-Jan-2011

Yizhi Xiao

Abdulsalam Elfowiris

yxiao32@uwo.ca

aelfowi@uwo.ca

28-Nov-2011

**Please explain how the biological agents are used in your project and how they are stored and disposed of. The BARF without this description will not be reviewed.**

my laboratory works with human saliva and oral bacteria and oral fungus present in sliva. All safety procedures realated to level 2 laboratory are used in our laboratory. All members always use gloves during the experiments and in the end of the day all benches are cledned with 70% methanol.

**Typos**

**Please include a ONE page research summary or teaching protocol in lay terms.  
Forms with summaries more than one page will not be reviewed.**

The acquired enamel pellicle (AEP) is a protein film with unique composition and properties which is formed in a selective manner on tooth enamel surfaces. The composition and the structure of this protein film are still mainly unknown but play functionally a vital role with important physiological/clinical implications. Its presence has important consequences both with respect to the protection of tooth enamel mineral and with respect to the nature of oral bacteria which colonize this tooth integument leading ultimately to bacterial colonization and the formation of dental plaque. The overall goal of this project is to gain insight into the biologic formation and function of the human acquired enamel pellicle. A major driving force of this application is therefore to use state-of-the-art proteomics to better characterize the components of the in vivo formed pellicle. It is also planned to explore the structural and functional properties of those in vivo AEP components by in situ and in vitro experiments.

The results of the work proposed herein will contribute significantly to the characterization of human AEP in vivo, and to our understanding of the biological functions of its components. In addition, this study may provide insights into the pathological processes underlying the initiation of dental caries and periodontal diseases. Moreover, the functional characterization of novel proteins and peptides may lead to the development of therapeutics aimed at controlling biofilm growth, remineralizing early carious lesions and providing new salivary substitutes.

**1.0 Microorganisms**

1.1 Does your work involve the use of biological agents?  YES  NO  
 (non-pathogenic and pathogenic biological agents including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA?  YES  NO

If YES, please give the name of the species candida albicans

What is the origin of the microorganism(s)? oral flora

Please describe the risk (if any) of escape and how this will be mitigated:  
**minimal risk**

*Please attach the CFIA permit.*

Please describe any CFIA permit conditions:  
**in vitro only**

1.2 Please complete the table below:

Full Scientific Name of Biological Agent(s)* (Be specific)	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/ Supplier	PHAC or CFIA Containment Level
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3

*\*Please attach a Material Safety Data Sheet or equivalent from the supplier if the bacterium used is not on this link:*  
[http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA\\_Ecoli\\_list.pdf](http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf)

Additional Comments: \_\_\_\_\_

## 2.0 Cell Culture

2.1 Does your work involve the use of cell cultures?  YES  NO  
 (If NO, please proceed to Section 3.0)

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	<input type="checkbox"/> Yes <input type="checkbox"/> No		Not applicable
Rodent	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Non-human primate	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Other (specify)	<input type="checkbox"/> Yes <input type="checkbox"/> No		

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Containment Level of each cell line	Supplier / Source of cell line(s)
Human	<input type="checkbox"/> Yes <input type="checkbox"/> No			
Rodent	<input type="checkbox"/> Yes <input type="checkbox"/> No			
Non-human primate	<input type="checkbox"/> Yes <input type="checkbox"/> No			
Other (specify)	<input type="checkbox"/> Yes <input type="checkbox"/> No			

*\*Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see [www.atcc.org](http://www.atcc.org))*

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required  1  2  2+  3

Additional Comments: \_\_\_\_\_

## 3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials?  YES  NO  
 If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/UNKNOWN	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid	Saliva, pellicle	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> Unknown	Oral Bacteria/Fungus	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Blood (fraction) or other Body Fluid		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (unpreserved)		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

Additional Comments: \_\_\_\_\_

#### 4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0?  YES  NO If **NO**, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done?  YES, complete table below  NO

Bacteria Used for Cloning *	Plasmid(s) **	Source of Plasmid	Gene Transformed or Transfected	Will there be a change due to transformation of the bacteria?	Will there be a change in the pathogenicity of the bacteria after the genetic modification?	What are the consequences due to the transformation of the bacteria?

\* Please attach a Material Safety Data Sheet or equivalent if available.

\*\* Please attach a plasmid map.

\*\*\*No Material Safety Data Sheet is required for the following strains of *E. coli*:

[http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA\\_Ecoli\\_list.pdf](http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf)

4.3 Will genetic modification(s) of bacteria and/or cells involving viral vectors be made?  YES, complete table below  NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results from transduction

\* Please attach a Material Safety Data Sheet or equivalent.

4.3.1 Will virus be replication defective?  YES  NO

4.3.2 Will virus be infectious to humans or animals?  YES  NO

4.3.3 Will this be expected to increase the containment level required?  YES  NO

#### 5.0 Will genetic sequences from the following be involved?

- ◆ HIV  NO  YES, specify
- ◆ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens  NO  YES, specify
- ◆ SV 40 Large T antigen  NO  YES
- ◆ E1A oncogene  NO  YES
- ◆ Known oncogenes  NO  YES, specify
- ◆ Other human or animal pathogen and or their toxins  NO  YES, specify

5.1 Is any work being conducted with prions or prion sequences?  NO  YES

Additional Comments: \_\_\_\_\_

## 6.0 Human Gene Therapy Trials

6.1 Will human clinical trials be conducted involving a biological agent?  YES  NO  
(including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)  
If no, please proceed to Section 7.0

6.2 If YES, please specify which biological agent will be used:  
Please attach a full description of the biological agent.

6.3 Will the biological agent be able to replicate in the host?  YES  NO

6.4 How will the biological agent be administered?

6.5 Please give the Health Care Facility where the clinical trial will be conducted:

6.6 Has human ethics approval been obtained?  YES, number:  NO  PENDING

## 7.0 Animal Experiments

7.1 Will live animals be used?  YES  NO If NO, please proceed to section 8.0

7.2 Name of animal species to be used

7.3 AUS protocol #

7.4 List the location(s) for the animal experimentation and housing.

7.5 Will any of the agents listed in section 4.0 be used in live animals  
 NO  YES, specify:

7.6 Will the agent(s) be shed by the animal:  
 YES  NO, please justify:

## 8.0 Use of Animal species with Zoonotic Hazards

8.1 Will any animals with zoonotic hazards or their organs, tissues, lavages or other body fluids including blood be used (see list below)?  YES  NO - If NO, please proceed to section 9.0

8.2 Will live animals be used?  YES  NO

8.3 If YES, please specify the animal(s) used:

- |                             |  |                             |
|-----------------------------|--|-----------------------------|
| ◆ Pound source dogs         | <input type="checkbox"/> YES                     | <input type="checkbox"/> NO |
| ◆ Pound source cats         | <input type="checkbox"/> YES                     | <input type="checkbox"/> NO |
| ◆ Cattle, sheep or goats    | <input type="checkbox"/> YES, species            | <input type="checkbox"/> NO |
| ◆ Non-human primates        | <input type="checkbox"/> YES, species            | <input type="checkbox"/> NO |
| ◆ Wild caught animals       | <input type="checkbox"/> YES, species & colony # | <input type="checkbox"/> NO |
| ◆ Birds                     | <input type="checkbox"/> YES, species            | <input type="checkbox"/> NO |
| ◆ Others (wild or domestic) | <input type="checkbox"/> YES, specify            | <input type="checkbox"/> NO |

8.4 If no live animals are used, please specify the source of the specimens:

## 9.0 Biological Toxins and Hormones

9.1 Will toxins or hormones of biological origin be used?  YES  NO If **NO**, please proceed to Section 10.0

9.2 If YES, please name the toxin(s) or hormones(s)  
Please attach information, such as a Material Safety Data Sheet, for the toxin(s) used.

9.3 What is the LD<sub>50</sub> (specify species) of the toxin or hormone

9.4 How much of the toxin or hormone is handled at one time\*?

9.5 How much of the toxin or hormone is stored\*?

9.6 Will any biological toxins or hormones be used in live animals?  YES  NO  
If **YES**, Please provide details:

\*For information on biosecurity requirements, please see:

[http://www.uwo.ca/humanresources/docandform/docs/healthandsafety/biosafety/Biosecurity\\_Requirements.pdf](http://www.uwo.ca/humanresources/docandform/docs/healthandsafety/biosafety/Biosecurity_Requirements.pdf)

Additional Comments: \_\_\_\_\_

## 10.0 Insects

10.1 Do you use insects?  YES  NO - If **NO**, please proceed to Section 11.0

10.2 If YES, please give the name of the species.

10.3 What is the origin of the insect?

10.4 What is the life stage of the insect?

10.5 What is your intention?  Initiate and maintain colony, give location:  
 "One-time" use, give location:

10.6 Please describe the risk (if any) of escape and how this will be mitigated:

10.7 Do you use insects that require a permit from the CFIA permit?  YES  NO  
If **YES**, Please attach the CFIA permit & describe any CFIA permit conditions:

**11.0 Plants**

- 11.1 Do you use plants?  YES  NO - If **NO**, please proceed to Section 12.0
- 11.2 If YES, please give the name of the species.
- 11.3 What is the origin of the plant?
- 11.4 What is the form of the plant (seed, seedling, plant, tree...)?
- 11.5 What is your intention?  Grow and maintain a crop  "One-time" use
- 11.6 Do you do any modifications to the plant?  YES  NO  
If yes, please describe:
- 11.7 Please describe the risk (if any) of loss of the material from the lab and how this will be mitigated:
- 11.8 Is the CFIA permit attached?  YES  NO  
If **YES**, Please attach the CFIA permit & describe any CFIA permit conditions:

**12.0 Import Requirements**

- 12.1 Will any of the above agents be imported?  YES, country of origin  NO  
If **NO**, please proceed to Section 13.0
- 12.2 Has an Import Permit been obtained from HC for human pathogens?  YES  NO
- 12.3 Has an import permit been obtained from CFIA for animal or plant pathogens?  YES  NO
- 12.4 Has the import permit been sent to OHS?  YES, please provide permit #  NO

**13.0 Training Requirements for Personnel Named on Form**

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS:

- ◆ Biosafety
- ◆ Laboratory and Environmental/Waste Management Safety
- ◆ WHMIS (Western or equivalent)
- ◆ Employee Health and Safety Orientation

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biological agents in Sections 1.0 to 9.0 have been trained.

**An X in the check box indicates you agree with the above statement...**   
**Enter Your Name** Walter Siqueira **Date:** April 27, 2012

**14.0 Containment Levels**

14.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required.  1  2  2+  3

14.2 Has the facility been certified by OHS for this level of containment?  
 YES, location and date of most recent biosafety inspection: **BIO-UWO-0235**  
 NO, please certify  
 NOT REQUIRED for Level 1 containment

14.3 Please indicate permit number (not applicable for first time applicants):

**15.0 Procedures to be Followed**

15.1 Are additional risk reduction measures necessary beyond containment level 1, 2, 2+ or 3 measures that are unique to these agents?  YES  NO  
If YES please describe:

15.2 Please outline what will be done if there is an exposure to the biological agents listed such as a needlestick injury or an accidental splash:  
**1. wash the exposure area with water; 2. call workplace health X. 85472**

15.3 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.shs.uwo.ca/workplace/workplacehealth.html>

**An X in the check box indicates you agree with the above statement...**   
**Enter Your Name** Walter Siqueira **Date:** April 27, 2012

15.4 Additional Comments: \_\_\_\_\_

**16.0 Approvals**

1) UWO Biohazards Subcommittee: SIGNATURE: \_\_\_\_\_  
Date: \_\_\_\_\_

2) Safety Officer for the University of Western Ontario SIGNATURE: \_\_\_\_\_  
Date: \_\_\_\_\_

3) Safety Officer for Institution where experiments will take place (if not UWO): SIGNATURE: \_\_\_\_\_  
Date: \_\_\_\_\_

Approval Number: \_\_\_\_\_ Expiry Date (3 years from Approval): \_\_\_\_\_

Special Conditions of Approval:



Home > Laboratory Biosafety and Biosecurity > Biosafety Programs and Resources > Pathogen Safety Data Sheets and Risk Assessment > Candida albicans - Material Safety Data Sheets (MSDS)

## Candida albicans - Material Safety Data Sheets (MSDS)

### MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

#### SECTION I - INFECTIOUS AGENT

**NAME:** *Candida albicans*

**SYNONYM OR CROSS REFERENCE:** Candidiasis, Thrush, Moniliasis

**CHARACTERISTICS:** Oval, budding yeast, produces pseudohyphae in culture and in tissues and exudates

#### SECTION II - HEALTH HAZARD

**PATHOGENICITY:** Mycosis of superficial layers of skin or mucous membranes (oral thrush, vulvovaginitis, paronychia, onychomycosis, intertrigo); ulcers or pseudomembranes in esophagus, gastrointestinal tract or bladder; hematogenous dissemination may produce lesions in kidney, spleen, lung, liver, prosthetic cardiac valve, eye, meninges, brain

**EPIDEMIOLOGY:** Worldwide

**HOST RANGE:** Humans

**INFECTIOUS DOSE:** Unknown

**MODE OF TRANSMISSION:** Endogenous spread (part of normal human flora); by contact with excretions of mouth, skin, and feces from patients or carriers; from mother to infant during childbirth; disseminated candidiasis may originate from mucosal lesions, unsterile narcotic injections, catheters

**INCUBATION PERIOD:** Variable

**COMMUNICABILITY:** Communicable for duration of lesions

#### SECTION III - DISSEMINATION

**RESERVOIR:** Humans (normal human flora)

**ZOOONOSIS:** None

**VECTORS:** None

#### SECTION IV - VIABILITY

**DRUG SUSCEPTIBILITY:** Sensitive to nystatin, clotrimazole, ketoconazole, fluconazole, amphotericin B for invasive candidiasis

**DRUG RESISTANCE:** Resistant strains have been described for all the above antifungal drugs

**SUSCEPTIBILITY TO DISINFECTANTS:** Sensitive to 1% sodium hypochlorite, 2% glutaraldehyde, formaldehyde; only moderately sensitive to 70% ethanol (phenolic may be substituted)

**PHYSICAL INACTIVATION:** Inactivated by moist heat (121°C for at least 15 min)

**SURVIVAL OUTSIDE HOST:** Survives outside of host, especially in moist, dark areas

## SECTION V - MEDICAL

**SURVEILLANCE:** Monitor for symptoms; microscopic demonstration of pseudohyphae and/or yeast cells in infected tissue or fluid; confirmation by culture

**FIRST AID/TREATMENT:** Administer antibiotic therapy as required

**IMMUNIZATION:** None

**PROPHYLAXIS:** None

## SECTION VI - LABORATORY HAZARDS

**LABORATORY-ACQUIRED INFECTIONS:** 2 reported laboratory-acquired infections with *Candida*

**SOURCES/SPECIMENS:** Sputum, bronchial washings, stool, urine, mucosal surfaces, skin or wound exudates, CSF, blood

**PRIMARY HAZARDS:** Accidental parenteral inoculation, exposure of mucous membranes to droplets and aerosols, ingestion

**SPECIAL HAZARDS:** None

## SECTION VII - RECOMMENDED PRECAUTIONS

**CONTAINMENT REQUIREMENTS:** Biosafety level 2 practices, containment equipment and facilities for the manipulation of this organism

**PROTECTIVE CLOTHING:** Laboratory coat; gloves when contact with infectious materials is unavoidable

**OTHER PRECAUTIONS:** None

## SECTION VIII - HANDLING INFORMATION

**SPILLS:** Allow aerosols to settle; wearing protective clothing, gently cover spill with absorbent paper towel and apply 1% sodium hypochlorite, starting at perimeter and working towards the centre; allow sufficient contact time (30 min) before clean up

**DISPOSAL:** Decontaminate before disposal; steam sterilization, chemical disinfection, incineration

**STORAGE:** In sealed containers that are appropriately labelled

## SECTION IX - MISCELLANEOUS INFORMATION

**Date prepared:** November 1999

**Prepared by:** Office of Laboratory Security, PHAC

Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright ©  
Health Canada, 2001